Company Analysis
Sign in

Lipocine Inc. (LPCN)

Nasdaq: LPCN · Pharmaceutical Preparations · Salt Lake City, US · filing with the SEC since 2011
Full chart Alerts Compare
Grade5.2
◀ Past 4.5● Present 5.9▶ Future 4.9
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lipocine Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
136
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Lipocine, Inc. its own name
US, as the owner printed on each patent
39 granted
120 published
Lipocine Inc. its own name
named as the applicant on its applications, in US
0 granted
16 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 6, 202111,052,096Steroidal compositionsPharmaceuticalsLipocine, Inc.
Apr 13, 202110,973,833High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Oct 13, 202010,799,513High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Jul 21, 202010,716,794High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Jul 14, 202010,709,71617-hydroxyprogesterone ester-containing oral compositions and related methodsPharmaceuticalsLipocine, Inc.
Feb 18, 202010,561,615Testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Mar 12, 201910,226,473High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Jul 17, 201810,022,38417-hydroxyprogesterone ester-containing oral compositions and related methodsPharmaceuticalsLipocine, Inc.
Apr 24, 20189,949,985High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Apr 17, 20189,943,527High-strength testosterone undecanoate compositionsPharmaceuticalsLipocine, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Jun 19, 20252025/0195539Testosterone Dodecanoate Compositions and MethodsPharmaceuticalsLipocine, Inc.
Jun 12, 20252025/0186354Steroidal Testosterone Ester Compositions and Preparation ThereofPharmaceuticalsLipocine, Inc.
Jan 30, 20252025/0032507Testosterone Dodecanoate Compositions and MethodsPharmaceuticalsLipocine, Inc. · patent 12,257,257 granted from it
Aug 1, 20242024/0252513Oral Allopregnanolone Compositions and Methods of UsePharmaceuticalsLipocine, Inc.
Jul 25, 20242024/0245708Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyPharmaceuticalsLipocine, Inc. · patent 12,156,881 granted from it
May 30, 20242024/0173335Oral Allopregnanolone Compositions and Methods of UsePharmaceuticalsLipocine, Inc. · patent 12,186,327 granted from it
May 30, 20242024/0173334Oral (17-ß)-3-Oxoandrost-4-EN-17-YL Tridecanoate TherapyPharmaceuticalsLipocine, Inc.
May 16, 20242024/0156837Compositions and Methods for Treating CNS DisordersPharmaceuticalsLipocine, Inc.
Jan 11, 20242024/0009206Steroidal CompositionsPharmaceuticalsLipocine, Inc.
Dec 7, 20232023/0390304Method and Composition for Treating EpilepsyPharmaceuticalsLipocine, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 9.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LPCN · research, not advice